Search for: "ACTAVIS"
Results 521 - 540
of 1,012
Sort by Relevance
|
Sort by Date
2 Mar 2015, 2:43 pm
. * Warner-Lambert v Actavis Mark 3: a "lyrical" solution to a painful patent disputeAfter the Patents Court ruling of Mr Justice Arnold in Warner-Lambert Company, LLC v Actavis Group Ptc EHF & Others, which Darren reported here, Jeremy has got some news to break on that painful patent war.* Blind faith not enough when proving bad faith: a case of ColourblindnessValentina reports on a fresh trade mark dispute that the General Court has just decided, Pangyrus Ltd v… [read post]
26 Feb 2015, 3:41 pm
On 21 January fellow Kat Darren posted "No pain for Actavis - Warner-Lambert fail to stop launch of generic pregabalin" (here). [read post]
23 Feb 2015, 2:55 am
Never too late 32 [week ending Sunday 8 February] –- Brazilian PTO’s delays | The Research Handbook on International Intellectual Property reviewed | Laura Smith-Hewitt | IP, women and leadership: the poll responses | Decline of West’s trust in innovation | Wikipedia public domain photos |CJEU in Case C-383/12 P Environmental Manufacturing LLP v OHIM | The Nordic IP Forum | The future of EPO’s BoA | Warner-Lambert v… [read post]
17 Feb 2015, 7:15 am
The University of San Francisco School of Law hosts After Actavis: Litigating Reverse Payments Feb. 27, 2015. [read post]
16 Feb 2015, 1:44 am
***** PREVIOUSLY, ON NEVER TOO LATE Never too late 32 [week ending Sunday 8 February] –- Brazilian PTO’s delays | The Research Handbook on International Intellectual Property reviewed | Laura Smith-Hewitt | IP, women and leadership: the poll responses | Decline of West’s trust in innovation | Wikipedia public domain photos |CJEU in Case C-383/12 P Environmental Manufacturing LLP v OHIM | The Nordic IP Forum |… [read post]
9 Feb 2015, 1:15 am
* Warner-Lambert v Actavis Mark 2, still at first instance: more on Swiss claims, Skinny Labels, and no StrikeoutDarren covers another Arnoldian decision in Warner-Lambert Company, LLC v Actavis Group Ptc EHF & Others [2015] EWHC 223 (Pat). [read post]
6 Feb 2015, 6:31 am
This Kat posted last month on the fascinating case of Warner-Lambert Company, LLC v Actavis Group Ptc EHF & Others [2015] EWHC 72 (Pat), in which Arnold J gave the first detailed UK consideration of what a Swiss-form claim means. [read post]
4 Feb 2015, 6:02 am
Investment grade acquirors benefited from a consistently strong financing environment throughout 2014 and finished the year with a flourish (including a $36 billion commitment backing Actavis’ acquisition of Allergan), while leveraged acquirors encountered more volatility, as lenders responded quickly to regulatory changes and market conditions, and both high-yield commitments and debt became more costly. [read post]
2 Feb 2015, 2:20 am
Not only did the Dutch Court disagree with the Courts of England and Wales on the matter of priority entitlement and hence validity , but also this ruling appears to be in contrast to the case last week [for which see Katpost here for the first instance and here and here for the appeal judgment] where Arnold J permitted Actavis to launch a product with a skinny label without requiring further measures such as… [read post]
29 Jan 2015, 10:31 am
But also, the judgment appears in stark contrast to the case last week where Arnold J permitted Actavis to launch a product (pregabalin) with a skinny label without requiring further measures such as overpackaging that were demanded by Pfizer; whereas here the Dutch court finds Sun Pharmaceutical guilty of indirect infringement despite the skinny label referring only to Paget's disease and not osteoporosis.In fairness, the prescribing and dispensing systems are different between… [read post]
28 Jan 2015, 1:02 am
In Warner -Lambert Company, LLC v Actavis Group Ptc EHF and Others [2015] EWHC 72 (Pat) (21 Jan 2015) Warner-Lambert LLC applied to Mr Justice Arnold for an interim injunction in the following terms: "1, The Defendants: (a) shall make it a condition of any oral or written agreement entered into with a pharmacy for the supply of Lecaent that the pharmacy shall use reasonable [read post]
26 Jan 2015, 4:03 am
.* No pain for Actavis: Warner-Lambert fail to stop launch of generic pregabalinSecond medical use claims, skinny labels, and public policy issues around healthcare are the topics addressed in Warner-Lambert Company, LLC v Actavis Group Ptc EHF & Others [2015] EWHC 72 (Pat) (21 January 2015), a decision that Mr Justice Arnold has just delivered and on which Darren timely comments in this post.* BREAKING NEWS: CJEU says exhaustion only applies to the tangible medium of… [read post]
21 Jan 2015, 1:35 pm
In a decision that is only moderately Arnoldian (139 paragraphs), Mr Justice Arnold refused today to grant an interim injunction that Warner Lambert had requested against Actavis [Warner -Lambert Company, LLC v Actavis Group Ptc EHF & Others [2015] EWHC 72 (Pat) (21 January 2015)]. [read post]
12 Jan 2015, 10:09 am
Staffing changes announced by New York State’s Governor Andrew M. [read post]
8 Jan 2015, 8:45 am
Michael Carrier, Rutgers Camden cautions How Not to Apply Actavis. [read post]
7 Dec 2014, 3:29 pm
Among the significant –- but, really, very-well indexed –- number of issues, the decision delves into novelty, inventive step, insufficiency by excessive claim breadth, added matter, and claim construction in light of the influential Actavis v Eli Lilly, another Arnoldian decision that the very same judge clarifies further in this ruling. [read post]
4 Dec 2014, 5:00 am
Bruce H. [read post]
2 Dec 2014, 7:35 am
The judge recorded:counsel pointed out that I had held in Actavis v Lilly at [112] that, in principle, a limitation made to a claim to avoid an objection of lack of clarity could be relied on as aid to construction. [read post]
1 Dec 2014, 6:05 am
Although the Valeant bid has failed, Pershing Square apparently will recognize a gain of well over $2 billion on consummation of the Actavis merger. [read post]
12 Nov 2014, 10:15 am
Janssen and Teva file to protect Chicago disclosing trade secrets: Back in the summer, the city of Chicago commenced proceedings against several pharmaceutical companies, including Janssen, Purdue Pharma LP, Teva and Actavis alleging that they dishonestly marketed opioid painkillers including Oxycontin and Percocet for the treatment of common and non-cancer related chronic pain resulting in a reported public health crisis of addiction and abuse. [read post]
